The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1293
A New Rotavirus Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Rotarix, an oral live-attenuated rotavirus vaccine, has been approved by the FDA for prevention of rotavirus gastroenteritis in infants and children. It is the third rotavirus vaccine to be approved. Rota-Shield was withdrawn from the market because of an association with intussusception. RotaTeq,1 an oral live, humanbovine reassortant rotavirus vaccine, is recommended by the American Academy of Pediatrics as a routine immunization.

ROTAVIRUS DISEASE — Rotavirus infects virtually all children by 5 years of age. Most infections are mild, but severe illness with fever, vomiting, diarrhea and dehydration can occur, especially in children between 6 and 24 months of age. In the US, rotavirus has been estimated to cause 60,000 hospitalizations and 37 deaths annually.2 Worldwide, rotavirus diarrhea kills more than 500,000 children every year, mostly in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Rotavirus Vaccine
Article code: 1293b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian